Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma

Medical University of Lodz

Status and phase

Unknown

Phase 4

Conditions

Asthma

Treatments

Biological: Novo Helisen Depot, Phostal

Study type

Interventional

Funder types

Other

Identifiers

NCT00496574

RNN-102-06-KE

Details and patient eligibility

About

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of SIT in children with asthma.

Full description

According to Global Initiative for Asthma treatment of asthma is based on avoidance of allergens, pharmacological treatment, and specific immunotherapy.

Enrollment

60 estimated patients

Sex

All

Ages

8 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients allergic to house dust mites
patients with moderate bronchial asthma
patients with controlled asthma
patients who were qualified for immunotherapy and gave written informed consent for immunotherapy (active treatment group)
patients who were qualified for immunotherapy and did not agree with this kind of treatment - did not give written informed consent for immunotherapy (control group)

Exclusion criteria

patients allergic for other perennial and seasonal allergens
patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator
medications that resulted in patient exclusion included:anti-parasites or oral corticosteroids within 6 months before the first visit.